Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

Abstract In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non‐small cell lung carcinoma harboring mesenchymal‐epithelial transition (MET) exon 14 skipping alterations. Herein, we present a ca...

Full description

Bibliographic Details
Main Authors: Kei Kunimasa, Takahisa Kawamura, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Kazumi Nishino, Toru Kumagai
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Thoracic Cancer
Subjects:
capmatinib
MET ex.14 skipping
peripheral edema
tepotinib
Online Access:https://doi.org/10.1111/1759-7714.14205

Internet

https://doi.org/10.1111/1759-7714.14205

Similar Items